Yüklüyor......
EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients
BACKGROUND: Small cell lung cancer (SCLC) is an aggressive and deadly neuroendocrine tumor derived from bronchial epithelial cells. Although it results in a 95% mortality rate, the development of targeted therapies for SCLCs has lagged behind. The aim of this study is to better research mutation cha...
Kaydedildi:
| Yayımlandı: | Onco Targets Ther |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5916454/ https://ncbi.nlm.nih.gov/pubmed/29720878 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S159612 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|